Consumo de cafeína e doença de Parkinson: uma mini-revisão das evidências recentes
DOI:
https://doi.org/10.34024/rnc.2021.v29.12641Palavras-chave:
cafeína, Doença de Parkinson, distúrbios neurodegenerativosResumo
Na ausência de tratamentos eficientes para a doença de Parkinson (DP), a pesquisa se concentrou na identificação de fatores ambientais potenciais, cuja modulação pode prevenir ou retardar a progressão deste distúrbio neurodegenerativo. Evidências epidemiológicas convincentes sugerem que o consumo de cafeína está inversamente associado ao risco de desenvolver DP. Outros achados experimentais demonstraram que a cafeína, ao direcionar particularmente os receptores de adenosina A2A (A2AR), protegeu os modelos animais de DP contra a perda de neurônios dopaminérgicos. A ação antagônica da cafeína nos receptores de adenosina não apenas desacelerou a neurodegeneração relacionada à DP, mas também melhorou os sintomas motores e não motores da DP em modelos animais. Aqui, revisamos os mecanismos de ação potenciais pelos quais a cafeína pode desempenhar um papel na redução do risco de DP. Também revisamos as evidências atuais dos benefícios do consumo de cafeína nos sintomas motores e não motores da DP. Finalmente, apontamos como esses achados promissores podem levar à identificação de novas abordagens para o tratamento eficaz da DP.
Downloads
Métricas
Referências
Fredholm BB, Bättig K, Holmén J, Nehlig EEZ. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133. https://pharmrev.aspetjournals.org/content/51/1/83.long
Nehlig A. Effects of coffee/caffeine on brain health and disease: What should i tell my patients? Prac Neurol 2016;16:89-95. https://doi.org/10.1136/practneurol-2015-001162
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim 2017;3:1-21. https://doi.org/10.1038/nrdp.2017.13
Nehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev. 2018;70:384-411. https://doi.org/10.1124/pr.117.014407
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - An update. Pharmacol Rev 2011;63:1-34. https://doi.org/10.1124/pr.110.003285
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: The state of the art. Physiol Rev 2018;98:1591-625. https://doi.org/10.1152/physrev.00049.2017
Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci 2006;29:647-54. https://doi.org/10.1016/j.tins.2006.09.004
Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. J Am Med Assoc 2000;283:2674-9. https://doi.org/10.1001/jama.283.20.2674
Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001;50:56-63. https://doi.org/10.1002/ana.1052
Hong CT, Chan L, Bai C-H. The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis. Nutrients 2020;12:1860. https://doi.org/10.3390/nu12061860
Sonsalla PK, Wong LY, Harris SL, Richardson JR, Khobahy I, Li W, et al. Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson’s disease. Exp Neurol 2012;234:482-7. https://doi.org/10.1016/j.expneurol.2012.01.022
Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 2001;21:RC143. https://doi.org/10.1523/JNEUROSCI.21-10-j0001.2001
Machado-Filho JA, Correia AO, Montenegro ABA, Nobre MEP, Cerqueira GS, Neves KRT, et al. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. Behav Brain Res 2014;264:116-25. https://doi.org/10.1016/j.bbr.2014.01.051
Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 2010;223:657-61. https://doi.org/10.1016/j.expneurol.2010.02.007
Luan Y, Ren X, Zheng W, Zeng Z, Guo Y, Hou Z, et al. Chronic caffeine treatment protects against α-synucleinopathy by reestablishing autophagy activity in the mouse striatum. Front Neurosci 2018;12:301. https://doi.org/10.3389/fnins.2018.00301
Yan R, Zhang J, Park HJ, Park ES, Oh S, Zheng H, et al. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson’s disease and DLB. Proc Natl Acad Sci USA 2018;115:E12053-62. https://doi.org/10.1073/pnas.1813365115
Coccurello R, Breysse N, Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacol 2004;29:1451-61. https://doi.org/10.1038/sj.npp.1300444
Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, et al. 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 2002;277:36040-4. https://doi.org/10.1074/jbc.M206830200
Altman RD, Lang AE, Postuma RB. Caffeine in Parkinson’s disease: A pilot open-label, dose-escalation study. Mov Disord 2011;26:2427-31. https://doi.org/10.1002/mds.23873
Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, et al. Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology 2012;79:651-8. https://doi.org/10.1212/WNL.0b013e318263570d
Cho BH, Choi SM, Kim JT, Kim BC. Association of Coffee Drinking and Non-motor Symptoms in Drug Naive, Early Stage Parkinson’s Disease, Parkinsonism and Related Disorders. Parkinsonism Relat Disord 2018;50:42-47. https://doi.org/10.1016/j.parkreldis.2018.02.016
Wills A-MA, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, et al. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord 2013;28:380-3. https://doi.org/10.1002/mds.25319
Nicoletti A, Zappia M, Mostile G, Arabia G, Nicoletti G, Quattrone A, et al. Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson’s disease: The FRAGAMP study. Mov Disord 2015;30:1854-6. https://doi.org/10.1002/mds.26459
Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson’s disease: A study in Swedish twins. Ann Neurol 2005;57:27-33. https://doi.org/10.1002/ana.20307
Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD). Neurology 2017;89:1795-803. https://doi.org/10.1212/WNL.0000000000004568
Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, et al. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology 2020;95:e3428-37. https://doi.org/10.1212/WNL.0000000000010863
Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 2018;90:e404-11. https://doi.org/10.1212/WNL.0000000000004888
Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, et al. Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease: Results of n-of-1 Trials. Front Neurol 2016;7:1. https://doi.org/10.3389/fneur.2016.00027
Gevaerd MS, Takahashi RN, Silveira R, Da Cunha C. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 2001;55:101-6. https://doi.org/10.1016/s0361-9230(01)00501-9
Prediger RDS, Da Cunha C, Takahashi RN. Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats. Behav Pharmacol 2005;16:209-18. https://doi.org/10.1097/01.fbp.0000166825.62130.9a
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2021 Daniella Balduino Victorino, Marcia Jonathas Guimarães-Marques, Astrid Nehlig
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Publicado: 2021-08-20
Português
English
Español
